期刊文献+

某院老年肺部感染患者抗感染药应用现况调查 被引量:1

A Cross-sectional Study on Existing Circumstance of Anti-infective Agents: Application for Elder Patients with Pulmonary Infections in a Certain Hospital
下载PDF
导出
摘要 目的通过对北京某医院干部病房老年肺部感染患者的回顾性调查,了解该人群抗感染药应用和老年肺部感染特点,探讨可能影响该人群肺部感染性疾病转归的危险因素。方法选取该医院2008~2009年干部病房收治的181名老年肺部感染住院患者的病例进行回顾性调查,采用SPSS17.0统计软件包进行统计分析处理。结果 181例老年患者平均年龄82.8±6.57岁,肺部感染性疾病如肺炎、慢性支气管炎、慢性阻塞性肺病(COPD)和急性支气管炎的治疗有效率分别为87.90%9、5.10%、96.00%和71.40%。影响肺部感染转归的因素为患者年龄(P=0.062)、所患基础病种类(P=0.024)和是否连续使用抗感染药(P=0.020),其OR值和95%CI分别为0.234(0.051,1.073)、0.223(0.061,0.819)和3.260(1.200,8.856)。结论影响该人群肺部感染治疗结局的因素有患者年龄、所患基础病种类和是否连续使用抗感染药。 Objective Understand current status of anti-infective agents application and main characteristics of pulmonary infections for elder subjects with pulmonary infections in the cadre wards in a certain hospital by investigating their charts.Discuss risk factors that may influence outcomes of pulmonary infections.Methods Investigate clinical charts of 181 elder patients retrospectively in the cadre wards in this hospital between 2008 and 2009.All data were analyzed by SPSS17.0 software package.Results The effective rate of pneumonia,chronic bronchitis,COPD and acute bronchitis is 87.90%,95.10%,96.00% and 71.40%,respectively.Factors that influence the outcomes of pulmonary infections are patients' age(P =0.062),type of underlying disease(P =0.024) and the continuing use of anti-infective agents(P =0.020).The OR value and 95%CI of those factors are 0.234(0.051,1.073),0.223(0.061,0.819) and 3.260(1.200,8.856).Conclusion Factors that influence outcomes of pulmonary infections are age of patients,type of underlying disease and continuing use of anti-infective agents.
出处 《中国药物警戒》 2011年第2期71-75,共5页 Chinese Journal of Pharmacovigilance
基金 国家科技部重大新药创制/创新药物研究与开发技术体系建设专题(2010ZX09401)
关键词 老年人 肺部感染 抗感染药 the elderly pulmonary infection anti-infective agents
  • 相关文献

参考文献11

  • 1Gaetan G-avazzi,Karl-Heinz Krause.Ageing and infection[J].The Lancet Infectious Diseases,2002,2(11):659-666.
  • 2P C.Appelbaum,S H.Gillespie,C J.Burley,et al.Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century:a review of gemifloxacin[J].International Journal of Antimicrobial Agents,2004,23:533-546.
  • 3H B.Fung,M O.Monteagudo-Chu.Community-Acquired Pneumonia in the Elderly Horatio[J].The American Journal of Geriatric Pharmacotherapy,2010,8(1):47-62.
  • 4叶任高,陆再英.内科学.第6版[M].北京:人民卫生出版社.2006.74-82.
  • 5C H.Lee,C L.Wu.An update on the management of hospital-acquired pneumonia in the elederly[J].International Journal of Gerontology,2008,2(4):183-195.
  • 6D J.MICK.Pneumonia in Eiders[J].Geriatric Nursing,1997:99-102.
  • 7S C.Nicholson,K P.High,S.Gothelf,et al.Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly[J].Diagnostic Microbiology and Infectious Disease,2002,44:109-116.
  • 8朱惠莉,龚瑾,符礼刚,李向阳.替考拉宁与万古霉素治疗老年人耐甲氧西林金葡菌肺部感染的评价[J].中国临床医学,2003,10(2):183-185. 被引量:10
  • 9B M.Greenberg,R L.Atmar,C E.Stager,et al.Bacteraemia in the elderly:predictors of outcome in an urban teaching hospital[J].Journal of Infection,2005,50:288-295.
  • 10卫生部,中华疾学会.中华人民共和国卫生部.抗菌药物临床应用指导原则[ES/OL].2004-08-19[2010-09-10].http:// www.moh.gov.cn/publicfiles/business/htmlfiles/wsb/pzcjd/200804/21154.htm.

二级参考文献7

  • 1[1]Spencer RC. Teicoplanin in gram - positive infection: microbiological aspects. Eur J Haematol Suppl, 1993, 54: 6~9.
  • 2[2]Smith SR, Cheesbrough J, Spearing R, et al. Randomised prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother, 1989, 33: 1193~1197.
  • 3[3]Sorrell TC, Collignon PJ. A Prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother, 1985, 16: 235~241.
  • 4[4]Charbonneau P, Harding I, Garaud JJ, et al. Teicoplanin: a well - tolerated and easily administered alternative to vancomycin for gram - positive infections in intensive cars patients. Intensive Care Med, 1994, 20(Suppl 4): S35~S42.
  • 5[5]Wood MJ. Comparative safety of teicoplanin and vancomycin. J Chemother, 2000, 5: 21~25.
  • 6[6]Yoshiyama Y, Yazaki T, Kanke M, et al. Nephrotoxicity of teicoplanin in rats. Jpn J Antibiot, 2000, 53(12): 660~666.
  • 7[7]Chow AW, Jewesson PJ, Kureishi A, et al. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients. EurJ Haematol Suppl, 1993, 54:18~24.

共引文献23

同被引文献1

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部